Q1 Earnings Forecast for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Equities research analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of Cresco Labs in a research note issued to investors on Tuesday, June 3rd. Roth Capital analyst W. Kirk expects that the company will post earnings of ($0.04) per share for the quarter. The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs' Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS and Q4 2026 earnings at ($0.03) EPS.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last posted its earnings results on Friday, May 30th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The business had revenue of $165.76 million during the quarter, compared to the consensus estimate of $164.37 million.

Several other equities research analysts also recently commented on the stock. Cormark raised shares of Cresco Labs from a "hold" rating to a "moderate buy" rating in a research note on Monday, March 17th. Canaccord Genuity Group downgraded shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the company. According to MarketBeat, Cresco Labs currently has a consensus rating of "Buy".

Cresco Labs Trading Up 1.9%

OTCMKTS:CRLBF traded up $0.01 during trading hours on Wednesday, hitting $0.54. The stock had a trading volume of 718,874 shares, compared to its average volume of 655,730. Cresco Labs has a one year low of $0.49 and a one year high of $2.05. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The company has a market cap of $265.30 million, a price-to-earnings ratio of -2.70 and a beta of 1.73. The business's 50 day moving average is $0.68 and its 200-day moving average is $0.83.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.